Charles Drake, MD, PhD
Following in the steps of ovarian cancer, PARP inhibitors have begun to show promise in metastatic castration-resistant prostate cancer. Olaparib (Lynparza), in particular, has demonstrated high response rates in patients with DNA-repair defects.
, Drake shared insight on the current status of both PARP inhibitors and immunotherapy in prostate cancer, emphasizing that immunotherapy is still very much a player in the prostate cancer field, with ongoing trials exploring checkpoint inhibitors.
OncLive: What is the excitement with PARP inhibitors in prostate cancer?
The paper that Dr Johann de Bono's group published in the New England Journal of Medicine a couple of years ago suggested that patients with mutations and DNA damage-repair genes demonstrated high responses to PARP inhibitors. The responses were nice and very meaningful, and some of them persisted for a very long time. That is a very important clinical finding.
... to read the full story